Elevance Health, Inc. (NYSE:ELV) Receives $440.90 Consensus PT from Analysts

Posted by Geri Gentry on Jul 30th, 2026

Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-three research firms that are presently covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $440.9048.

ELV has been the topic of several recent analyst reports. Bank of America upped their price target on Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a research report on Thursday, June 4th. Truist Financial raised their price objective on Elevance Health from $450.00 to $475.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Guggenheim lifted their target price on Elevance Health from $399.00 to $455.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Sanford C. Bernstein set a $488.00 target price on Elevance Health in a report on Thursday, July 16th. Finally, Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th.

Read Our Latest Stock Report on ELV

Elevance Health Stock Performance

Shares of ELV opened at $376.21 on Thursday. The company has a 50-day moving average of $397.65 and a two-hundred day moving average of $356.66. The stock has a market cap of $81.59 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 2.22 and a beta of 0.67. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.52 and a quick ratio of 1.52. Elevance Health has a one year low of $273.71 and a one year high of $436.24.

Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The business had revenue of $49.83 billion for the quarter, compared to analyst estimates of $48.88 billion. During the same quarter in the previous year, the business earned $8.84 earnings per share. The firm’s revenue was up .8% compared to the same quarter last year. On average, equities research analysts expect that Elevance Health will post 27.04 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.8%. The ex-dividend date is Thursday, September 10th. Elevance Health’s dividend payout ratio is currently 30.58%.

Insiders Place Their Bets

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the sale, the director owned 10,734 shares in the company, valued at $4,312,599.18. This represents a 1.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Elevance Health

A number of hedge funds have recently modified their holdings of ELV. WealthCollab LLC boosted its position in Elevance Health by 42.2% during the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after purchasing an additional 27 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in Elevance Health in the 4th quarter worth about $31,000. J.Safra Asset Management Corp purchased a new stake in shares of Elevance Health during the 4th quarter worth about $32,000. ORG Partners LLC raised its stake in shares of Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Elevance Health during the 4th quarter valued at about $38,000. 89.24% of the stock is owned by institutional investors and hedge funds.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

Positive Sentiment: Zacks Research raised multiple earnings estimates. The firm increased its FY2026 EPS forecast to $27.06 from $26.79, FY2027 to $28.83 from $28.51, and FY2028 to $32.49 from $31.77. It also raised estimates for Q2 2027, Q4 2027, Q1 2028 and Q2 2028, indicating improving expectations for Elevance Health’s longer-term profitability.
Positive Sentiment: Insider buying provided a vote of confidence. A report highlighted purchases of Elevance Health shares by the company’s CEO and chairman, a potentially supportive signal because insider buying can suggest management views the stock as undervalued. Elevance Health Pick of the Week at Smart Insider Following CEO, Chairman Share Purchases
Neutral Sentiment: Peer comparison offers limited direct impact. A head-to-head survey compared Elevance Health with Aeon Global Health, but the article does not indicate a material change to ELV’s earnings outlook or valuation. Head to Head Survey: Elevance Health and Aeon Global Health
Negative Sentiment: Analyst commentary remains cautious. A Seeking Alpha analysis said Elevance Health has upside potential but is “not yet a buy,” which may limit buying interest. Investors may also be focused on near-term earnings pressure: the latest quarterly EPS of $7.45 exceeded estimates but declined from $8.84 in the prior-year period. Elevance Health Has Upside, But Not Yet A Buy

Elevance Health Company Profile

(Get Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.